Safety signal detection

In this talk, the focus is safety signal detection, supported by coverage of preclinical safety assessment, clinical monitoring during trials, and robust post marketing pharmacovigilance, illustrating how safety signal detection evolves throughout a drug's life cycle. We'll discuss methodologies for identifying, quantifying, and reporting adverse drug reactions in both trial and real world settings, as well as strategies for overcoming challenges such as incomplete data and confounding factors. Finally, we'll review how regulatory authorities respond to emerging safety signals to ensure patient safety and maintain public trust in medicines. Today, we're exploring safety signal detection, the process of identifying, assessing and acting on emerging risks associated with medicines throughout their life cycle. Signal detection evolves as a drug moves from pre clinical development to clinical testing and into real world use. We'll explore preclinical safety assessment, clinical monitoring, robust post marketing pharmacovigilance, real world signal detection, and regulatory responses, key to ensuring patient safety. The journey of safety signal detection starts before human exposure to a new compound. In the preclinical phase, in vitro and in vivo studies, identify potential toxicities and organ specific risks by examining dose response, off target effects, and mechanistic toxicity. Theoretical risks or known unknowns are also tracked here and